BMS Names New Board Member - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BMS Names New Board Member



Bristol-Myers Squibb’s board of directors has elected Thomas J. Lynch, Jr., MD to its board, effective Jan. 1, 2014. Lynch will serve as a member of the Science and Technology Committee of the Board of Directors.

Lynch is currently the director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven. He is also the Richard Sackler and Jonathan Sackler Professor of Medical Oncology at Yale-New Haven. He has held these positions since 2009. From 1993 to 2009, he was a professor of medicine at Harvard Medical School and chief of hematology and oncology at Massachusetts General Hospital (MGH) Cancer Center. He also served as director of the Center for Thoracic Cancers at MGH and director of medical oncology at the MGH Thoracic Oncology Center.

Source: Bristol-Myers Squibb

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here